Nat Commun:血栓治疗新突破!

2017-11-10 佚名 medicalxpress

生物过程中的血液凝结具有双重作用。当你出血时,这是一个救星,但是同时,它会引起心脏病、中风和其他严重的医疗问题。如果血块长得太大,被血流(栓子)排出的碎片会堵塞肺部或脑部的下游血管,导致肺栓塞或缺血性中风等危及生命的并发症。因此,一旦凝块形成,即使出于有利的原因,在伤口愈合开始后它也必须缩小并消失,以保持正常的血流。

生物过程中的血液凝结具有双重作用。当你出血时,这是一个救星,但是同时,它会引起心脏病、中风和其他严重的医疗问题。如果血块长得太大,被血流(栓子)排出的碎片会堵塞肺部或脑部的下游血管,导致肺栓塞或缺血性中风等危及生命的并发症。因此,一旦凝块形成,即使出于有利的原因,在伤口愈合开始后它也必须缩小并消失,以保持正常的血流。

虽然科学家们对血液凝结的形式有了很多的了解,但是人们对于他们是如何凝结的知之甚少。

最近在“自然通讯”上发表的一篇文章中,加利福尼亚大学河滨分校和宾夕法尼亚大学医学院的研究人员使用了高倍显微镜和流变测量技术在细胞水平实时监测研究对象在外力的作用下如何反应。这些发现将有助于开发新的凝血障碍治疗方法。

由于受伤或炎症,血液中的血小板被激活,变粘,并与一种称为纤维蛋白的纤维状蛋白质结合在一起,形成网状栓塞(血块),使组织停止流血。血小板在凝块收缩中起着核心作用,但是直到现在,科学家还没有能够准确地显示他们是如何完成的。

如文中所述,当血小板形成称为丝状伪足的手状突起时,发生凝块收缩。然后这些丝状伪足附着在纤维蛋白纤维上,并相互作用。血小板将纤维蛋白保留在微小的紧密缠绕的束中,因此重塑纤维蛋白网以使其更致密和僵硬。卷取作用也使血小板和血小板团聚在一起,减少血块的总体积,然后被纤维蛋白溶解酶完全溶解。

Alber说,这项研究结果突显了丝状伪足的新作用,以前认为这种作用可以帮助细胞移动并感知其环境。

Alber说:“到现在为止,我们对于单个血小板或小团血小板如何对纤维蛋白纤维施加收缩力以及这种张力如何破坏凝块结构并减小其大小知之甚少。 “通过这项研究,我们发现了一种新的丝状伪足功能,即它们能重新排列纤维蛋白基质引起凝块收缩,这些发现将有助于血栓溶解治疗的设计,以加强血液疾病的治疗,包括血栓形成和血栓栓塞。”

原始出处:

Oleg V. Kim, Rustem I. Litvinov, Mark S. Alber, et.al. Quantitative structural mechanobiology of platelet-driven blood clot contraction. Nature Communication

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882628, encodeId=a824188262854, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Sep 13 05:22:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724958, encodeId=7a451e2495899, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 11 14:22:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087194, encodeId=cc57208e19403, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 04 13:22:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260514, encodeId=f10026051450, content=血栓治疗新突破., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Nov 11 11:45:22 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2018-09-13 一叶知秋
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882628, encodeId=a824188262854, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Sep 13 05:22:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724958, encodeId=7a451e2495899, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 11 14:22:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087194, encodeId=cc57208e19403, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 04 13:22:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260514, encodeId=f10026051450, content=血栓治疗新突破., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Nov 11 11:45:22 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2018-07-11 zxxiang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882628, encodeId=a824188262854, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Sep 13 05:22:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724958, encodeId=7a451e2495899, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 11 14:22:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087194, encodeId=cc57208e19403, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 04 13:22:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260514, encodeId=f10026051450, content=血栓治疗新突破., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Nov 11 11:45:22 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2018-10-04 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882628, encodeId=a824188262854, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Sep 13 05:22:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724958, encodeId=7a451e2495899, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 11 14:22:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087194, encodeId=cc57208e19403, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Oct 04 13:22:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260514, encodeId=f10026051450, content=血栓治疗新突破., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Nov 11 11:45:22 CST 2017, time=2017-11-11, status=1, ipAttribution=)]
    2017-11-11 jyzxjiangqin

    血栓治疗新突破.

    0

相关资讯

这大概是他最后一次血栓栓塞了吧……

虽然房颤很普遍,连国内大型流行病学调查显示,其患病率接近百分之一,减少血栓栓塞并发症是重要的目标,故抗凝是房颤治疗的重要内容。但要在国内目前的医疗现状下做好这项工作,难度相当大。

JACC:下腔静脉滤过器的有效性和安全性研究

下腔静脉滤过器被广泛用来预防肺动脉栓塞(PE)的发生,然而,这种装置的长期安全性和有效性尚未阐明。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估下腔静脉滤过器有效性和安全性的荟萃分析。本研究搜索了截至2016年10月3日PubMed, the Cochrane Central Register of Controlled Trials和ClinicalTrials.gov数据库的相关随机对

急性肺血栓栓塞症rt-PA静脉溶栓致严重低血压

53岁男性,因双下肢外伤1个月,咳嗽,左侧胸痛2天入院。入院诊断:1.急性肺栓塞,2.左下肢深静脉血栓形成。给予重组组织型纤溶酶原激活物(rt-PA)100mg静脉溶栓,但溶栓至1小时10分钟,患者突感头晕,胸闷,面色苍白,查BP 30/0mmHg,HR 40次/分,心电图显示心动过缓,这是为何?

Pharmacoepidemiol Drug Saf:肝素诱导性血小板减少症:血栓栓塞并发症的风险因素是什么?

2017年10月,发表在《Pharmacoepidemiol Drug Saf》的一项由德国科学家进行的研究,考察了免疫介导的肝素诱导性血小板减少症(HIT2型,HIT)发生血栓栓塞并发症的相关风险因素。

NEJM:血栓形成倾向检测流程和推荐意见

在临床上经常进行血栓形成倾向检测;哪些患者需要检测,如何解读这些结果尚不清楚。截止到目前尚未发表血栓形成倾向检测的指南。ACCP-9指南以及2016年静脉血栓栓塞(VTE)更新版并未对血栓形成倾向检测给出指导性建议,2013年美国血液学会对于存在短暂性重要危险因素的VTE患者不推荐进行血栓形成倾向检测。英国血液病学委员会遗传性血栓形成倾向临床指南认为“关于何种患者或家属需要进行检测,不可能给出确切

JAMA Surg:抗Xa因子水平调整依诺肝素用量治疗方案不能降低患者创伤后的静脉血栓发生率

研究认为,对于严重创伤患者,根据抗Xa因子水平调整依诺肝素用量不能显著降低患者静脉血栓发生率